Global Obesity Drug Leadership: Lilly's Consumer-Centric Approach

Eli Lilly is set to expand its leadership in the obesity drug market internationally, adopting a consumer-centered approach that has proven successful in the U.S. The company is leveraging partnerships with telehealth and digital platforms to reach more patients directly. Countries like Britain, China, and the UAE are part of this strategic plan.

Lilly's model, already effective in the U.S., is now being applied in regions such as Australia and China through collaboration with e-commerce giants Alibaba and JD.com. These partnerships aim to facilitate access to weight-loss drugs for patients paying out-of-pocket.

Patrik Jonsson, Lilly's international president, reinforced the importance of a strong consumer focus. The company is optimistic about replicating its U.S. market successes on a global scale.

(With inputs from agencies.)